We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adeno-associated virus-mediated neuroglobin overexpression ameliorates the N-methyl-N-nitrosourea-induced retinal impairments: a novel therapeutic strategy against photoreceptor degeneration.
- Authors
Ye Tao; Zhen Yang; Wei Fang; Zhao Ma; Yi Fei Huang; Zhengwei Li; Tao, Ye; Yang, Zhen; Fang, Wei; Ma, Zhao; Huang, Yi Fei; Li, Zhengwei
- Abstract
Retinal degeneration (RD) is a heterogeneous group of inherited dystrophies leading to blindness. The N-methyl-N-nitrosourea (MNU)-administered mouse is used as a pharmacologically induced RD animal model in various therapeutic investigations. The present study found the retinal neuroglobin (NGB) expression in the MNU-administered mice was significantly lower than in normal controls, suggesting NGB was correlated with RD. Subsequently, an adeno-associated virus (AAV)-2-mCMV-NGB vector was delivered into the subretinal space of the MNU-administered mice. The retinal NGB expression of the treated eye was upregulated significantly in both protein and mRNA levels. Further, we found NGB overexpression could alleviate visual impairments and morphological devastations in MNU-administered mice. NGB overexpression could rectify apoptotic abnormalities and ameliorate oxidative stress in MNU-administered mice, thereby promoting photoreceptor survival. The cone photoreceptors in MNU-administered mice were also sensitive to AAV-mediated NGB overexpression. Taken together, our findings suggest that manipulating NGB bioactivity via gene therapy may represent a novel therapeutic strategy against RD. Future elucidation of the exact role of NGB would advance our knowledge about the pathological mechanisms underlying RD.
- Subjects
ADENO-associated virus; RETINAL degeneration treatment; GENETIC overexpression; NITROSOUREAS; PHOTORECEPTORS
- Publication
Therapeutics & Clinical Risk Management, 2017, Vol 13, p1379
- ISSN
1176-6336
- Publication type
journal article
- DOI
10.2147/TCRM.S144822